🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 3 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/04/2025 | 499,00 | 501,91 | 493,12 | 500,49 | +0,94% | 1,76% | 1.030.700 |
| 14/04/2025 | 487,01 | 498,64 | 484,20 | 495,83 | +2,40% | 2,97% | 1.362.200 |
| 11/04/2025 | 477,11 | 486,97 | 468,30 | 484,22 | +1,84% | 3,91% | 1.574.200 |
| 10/04/2025 | 478,99 | 480,00 | 455,69 | 475,49 | -1,41% | 5,08% | 2.252.300 |
| 09/04/2025 | 460,02 | 487,15 | 452,00 | 482,30 | +2,10% | 7,64% | 3.171.700 |
| 08/04/2025 | 477,20 | 483,94 | 466,98 | 472,37 | -0,46% | 3,55% | 2.391.400 |
| 07/04/2025 | 465,93 | 481,74 | 448,14 | 474,56 | -0,01% | 7,21% | 2.712.400 |
| 04/04/2025 | 484,35 | 499,07 | 473,64 | 474,62 | -1,94% | 5,25% | 2.884.300 |
| 03/04/2025 | 480,01 | 494,49 | 480,01 | 484,01 | +0,11% | 3,02% | 2.063.800 |
| 02/04/2025 | 481,64 | 487,93 | 480,42 | 483,49 | -0,26% | 1,56% | 988.400 |
| 01/04/2025 | 486,27 | 491,93 | 480,95 | 484,74 | -0,02% | 2,26% | 1.249.500 |
| 31/03/2025 | 487,13 | 487,13 | 471,50 | 484,82 | -1,60% | 3,21% | 2.231.900 |
| 28/03/2025 | 504,79 | 504,79 | 491,37 | 492,69 | -1,96% | 2,66% | 1.280.600 |
| 27/03/2025 | 498,59 | 506,54 | 498,59 | 502,55 | +0,45% | 1,59% | 1.233.500 |
| 26/03/2025 | 504,87 | 508,64 | 497,78 | 500,28 | -1,72% | 2,15% | 1.328.700 |
| 25/03/2025 | 511,78 | 512,71 | 503,99 | 509,04 | -0,53% | 1,70% | 1.006.600 |
| 24/03/2025 | 505,00 | 513,98 | 501,00 | 511,74 | +1,70% | 2,57% | 1.237.600 |
| 21/03/2025 | 505,42 | 510,08 | 501,07 | 503,20 | -1,37% | 1,78% | 2.280.500 |
| 20/03/2025 | 509,99 | 515,67 | 505,49 | 510,18 | -0,46% | 2,00% | 1.064.700 |
| 19/03/2025 | 512,01 | 514,82 | 505,00 | 512,52 | +0,06% | 1,92% | 1.124.000 |
| 18/03/2025 | 513,08 | 516,50 | 508,52 | 512,23 | -0,30% | 1,56% | 1.335.400 |
| 17/03/2025 | 505,20 | 517,20 | 504,00 | 513,76 | +1,78% | 2,61% | 1.108.800 |
| 14/03/2025 | 507,00 | 519,68 | 502,26 | 504,77 | +0,37% | 3,44% | 1.386.500 |
| 13/03/2025 | 493,79 | 512,75 | 488,00 | 502,92 | +1,51% | 5,01% | 1.699.800 |
| 12/03/2025 | 484,62 | 496,64 | 483,09 | 495,42 | +1,45% | 2,80% | 1.368.700 |
| 11/03/2025 | 496,86 | 497,50 | 480,28 | 488,34 | -2,33% | 3,47% | 1.389.800 |
| 10/03/2025 | 483,39 | 503,89 | 480,38 | 500,01 | +2,40% | 4,86% | 1.796.700 |
| 07/03/2025 | 485,71 | 492,34 | 482,82 | 488,29 | +0,53% | 1,96% | 1.198.300 |
| 06/03/2025 | 490,15 | 491,62 | 479,78 | 485,72 | -1,20% | 2,42% | 1.325.400 |
| 05/03/2025 | 485,25 | 495,54 | 483,54 | 491,64 | +1,11% | 2,47% | 1.147.300 |